Summary of Neurocrine Biosciences Conference Call Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date of Conference**: March 17, 2026 - **Key Speakers**: Kyle Gano (CEO), Todd Tushla (Head of IR) Key Points 1. Financial Performance - **2025 Revenue**: Approximately $2.8 billion, representing a **22% year-over-year growth** [4] - **Ingrezza Revenue**: $2.51 billion in 2025, with a **9% year-over-year growth** and double-digit volume growth [5] - **2026 Revenue Guidance**: Expected to be between **$2.7 billion and $2.8 billion** [11] - **Price Trends**: Anticipated **4%-5% price decline** year-over-year for Ingrezza due to expanded access [12] 2. Product Performance - **Ingrezza**: - Eighth year of commercialization with strong sales performance. - Focus on expanding prescriber base, targeting **30% new prescribers** [6] - Anticipated strong year with **double-digit volume growth** [31] - **CRENESSITY**: - First year of commercial sales generated **$300 million** in revenue, capturing **10% of the CH market** [7] - High reimbursement rates with **80% of dispensed scripts reimbursed** [7] - Focus on educational support for physicians and patients to change the standard of care [8] 3. Pipeline and Future Developments - **Phase 3 Trials**: - Osavampator and direclidine expected to deliver data in **2027** [8] - NBI-570 (M1M4 dual agonist) in schizophrenia and NBI-890 (next-generation VMAT2 inhibitor) in phase 2 trials [9][10] - **Next-Generation VMAT2 Program**: - Focus on long-acting injectable formulations to improve patient compliance [72] - **CRF1 Antagonist (NBIP-1435)**: - In phase 1, moving to phase 2/3 later this year, offering a long-acting injectable option [80] 4. Market Dynamics and Competitive Landscape - **Market Access**: - 70% of TD and HD patients under existing contracts, providing a strong market position [36] - **Competitor Analysis**: - Teva's MFP implementation in 2027 and 2028 may impact pricing strategies [36] - **Regulatory Environment**: - Ongoing negotiations with Medicare plans for 2027, with expectations for adjacent MFP products [37] 5. Strategic Focus - **Execution and Data Delivery**: - Emphasis on executing current strategies and delivering data across phase 2 and phase 3 programs in 2027 [10] - **Sustainable Innovation**: - Commitment to a diversified pipeline and innovation engine to support long-term growth [86] 6. Additional Insights - **Patient Compliance**: - Importance of addressing patient reauthorization processes and maintaining access to prescriptions [44] - **Market Sensitivity**: - Anticipation of emotional responses to new patient start forms, with a focus on consistent growth trends [42] Conclusion Neurocrine Biosciences is positioned for continued growth with a strong financial profile, a diversified product portfolio, and a robust pipeline of upcoming clinical data. The company is focused on execution and market access strategies to navigate competitive pressures and regulatory challenges while aiming to enhance patient care through innovative therapies.

Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2025 Earnings Presentation February 1 1, 2026 Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our produc ...

Financial Performance - Total Neurocrine net product sales reached $790 million, representing a 16% quarter-over-quarter (QoQ) growth and a 28% year-over-year (YoY) growth compared to Q2 2025 and Q3 2024, respectively[11] - INGREZZA net product sales were $687 million, showing a 10% QoQ growth and a 12% YoY growth compared to Q2 2025 and Q3 2024, respectively[11] - CRENESSITY net product sales amounted to $98 million, including 540 total new patient enrollment forms[11] - The company reaffirmed INGREZZA net sales guidance at $2500 million - $2550 million for the full year 2025[11] - Cash and investments totaled approximately $2100 million as of September 30, 2025[7] Research and Development - The company initiated all Phase 3 registrational studies for osavampator (AMPA PAM) as an adjunctive therapy for the treatment of MDD in adults and direclidine (Selective M4 Agonist) for the treatment of Schizophrenia[11] - The company expects to report top-line data in Q4 2025 for the Phase 3 study of valbenazine for Dyskinetic Cerebral Palsy and the Phase 2 study of NBI-'770 (NMDA NR2B NAM) for the treatment of MDD[11] - The company plans to initiate Phase 2 studies in Q4 2025 for direclidine for Bipolar Mania and NBI-'570 (Selective Dual M1 / M4 Agonist) for Schizophrenia[11] Commercial Strategy - The company plans to expand INGREZZA and CRENESSITY sales teams in Q4 2025, with completion expected by the end of Q1 2026, to maximize commercial momentum[11] - CRENESSITY has achieved approximately 80% reimbursement coverage for dispensed scripts[11] Pipeline Development - The company has a pipeline of 12 programs, including the first biologic program NBIP-'1435[8] - The company is advancing additional internally developed pre-clinical programs, including biologics, into first-in-human studies[11]